Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 8/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.49 |
| ▸ | HINT1 | P49773 | 4/20 | 0.49 |
| ▸ | GSK3A | P49840 | 2/20 | 0.47 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
| ▸ | NT5E | P21589 | 1/20 | 0.46 |
| ▸ | PNP | P00491 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18042134 | 0.92 | TYMP (0.68) | TYMPHPGDTAS1R3TAS1R1HINT1 | |
| SCHEMBL1738400 | 0.92 | TYMP (0.68) | TYMPHPGDTAS1R3TAS1R1HINT1 | |
| SCHEMBL16702978 | 0.92 | TYMP (0.68) | TYMPHPGDTAS1R3TAS1R1HINT1 | |
| SCHEMBL21905181 | 0.91 | TYMP (0.67) | TYMPHPGDTAS1R3TAS1R1HINT1 | |
| SCHEMBL6420722 | 0.90 | TYMP (0.79) | TYMPHPGDHINT1GSK3ARPS6KA3 | |
| SCHEMBL20691329 | 0.89 | TYMP (0.81) | TYMPGSK3ARPS6KA3MAPK14ADORA1 | |
| SCHEMBL28827056 | 0.89 | TYMP (0.54) | TYMPHPGDTAS1R3TAS1R1HINT1 | |
| SCHEMBL19841776 | 0.89 | TYMP (0.59) | TYMPTAS1R3TAS1R1HINT1NT5E | |
| SCHEMBL21979489 | 0.88 | TYMP (0.53) | TYMPHPGDTAS1R3TAS1R1HINT1 | |
| SCHEMBL19128529 | 0.88 | TYMP (0.53) | TYMPHPGDTAS1R3TAS1R1HINT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10730904-B2 | Method for liquid-phase synthesis of nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-04 | — | — | US | disclosed |
| US-20190135852-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-09 | — | — | US | disclosed |
| US-20150315229-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315229-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | POLM, POLRMT, RNMT | TYMP 123/4885HPGD 4133/4885TAS1R3 1674/4885 |
| US-20190135852-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | RNGTT, POLR2H, POLR2E | TYMP 165/4885HPGD 2716/4885TAS1R3 1563/4885 |
| US-10730904-B2 | Method for liquid-phase synthesis of nucleic acid | RNGTT, POLR2H, POLR2E | TYMP 257/4885HPGD 3414/4885TAS1R3 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.